CN111971285A - 咪唑并吡咯酮化合物及其应用 - Google Patents

咪唑并吡咯酮化合物及其应用 Download PDF

Info

Publication number
CN111971285A
CN111971285A CN201980018920.7A CN201980018920A CN111971285A CN 111971285 A CN111971285 A CN 111971285A CN 201980018920 A CN201980018920 A CN 201980018920A CN 111971285 A CN111971285 A CN 111971285A
Authority
CN
China
Prior art keywords
compound
group
alkyl
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980018920.7A
Other languages
English (en)
Other versions
CN111971285B (zh
Inventor
陈新海
颜小兵
黄江磊
聂岳坤
胡国平
黎健
陈曙辉
董加强
王铁林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Luoxin Biotechnology Shanghai Co ltd
Medshine Discovery Inc
Shandong Luoxin Pharmaceutical Group Co Ltd
Original Assignee
Luoxin Biotechnology Shanghai Co ltd
Medshine Discovery Inc
Shandong Luoxin Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Luoxin Biotechnology Shanghai Co ltd, Medshine Discovery Inc, Shandong Luoxin Pharmaceutical Group Co Ltd filed Critical Luoxin Biotechnology Shanghai Co ltd
Publication of CN111971285A publication Critical patent/CN111971285A/zh
Application granted granted Critical
Publication of CN111971285B publication Critical patent/CN111971285B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

本发明公开了新的一类具有咪唑并吡咯酮结构的MDM2‑p53抑制剂的化合物，具体公开了式(I‑1)和(I‑2)所示化合物及其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (26)

  1. PCT国内申请，权利要求书已公开。
CN201980018920.7A 2018-03-12 2019-03-12 咪唑并吡咯酮化合物及其应用 Active CN111971285B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201810201653 2018-03-12
CN2018102016534 2018-03-12
CN201811157824 2018-09-30
CN2018111578244 2018-09-30
PCT/CN2019/077845 WO2019174576A1 (zh) 2018-03-12 2019-03-12 咪唑并吡咯酮化合物及其应用

Publications (2)

Publication Number Publication Date
CN111971285A true CN111971285A (zh) 2020-11-20
CN111971285B CN111971285B (zh) 2023-08-15

Family

ID=67907436

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980018920.7A Active CN111971285B (zh) 2018-03-12 2019-03-12 咪唑并吡咯酮化合物及其应用

Country Status (5)

Country Link
US (1) US11639355B2 (zh)
EP (1) EP3766883B1 (zh)
JP (1) JP7358372B2 (zh)
CN (1) CN111971285B (zh)
WO (1) WO2019174576A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021047466A1 (zh) * 2019-09-12 2021-03-18 罗欣药业(上海)有限公司 一种p53-MDM2抑制剂的晶型及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203952A (zh) * 2012-01-26 2014-12-10 诺华股份有限公司 咪唑并吡咯烷酮化合物
WO2015198266A1 (en) * 2014-06-26 2015-12-30 Novartis Ag Intermittent dosing of mdm2 inhibitor
CN105209467A (zh) * 2013-05-27 2015-12-30 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
WO2017037579A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2185556A1 (en) * 2007-08-27 2010-05-19 Wyeth a Corporation of the State of Delaware Imidazopyridine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
CN105848682A (zh) 2013-12-23 2016-08-10 诺华股份有限公司 药物组合
CN110418790B (zh) * 2017-03-06 2022-05-17 罗欣药业(上海)有限公司 作为p53-MDM2抑制剂的咪唑并吡咯酮化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104203952A (zh) * 2012-01-26 2014-12-10 诺华股份有限公司 咪唑并吡咯烷酮化合物
CN105209467A (zh) * 2013-05-27 2015-12-30 诺华股份有限公司 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
WO2015198266A1 (en) * 2014-06-26 2015-12-30 Novartis Ag Intermittent dosing of mdm2 inhibitor
WO2017037579A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Mdm2 inhibitors and combinations thereof

Also Published As

Publication number Publication date
WO2019174576A1 (zh) 2019-09-19
JP2021517570A (ja) 2021-07-26
CN111971285B (zh) 2023-08-15
EP3766883A1 (en) 2021-01-20
US20210230164A1 (en) 2021-07-29
EP3766883B1 (en) 2022-09-28
EP3766883A4 (en) 2021-03-24
JP7358372B2 (ja) 2023-10-10
US11639355B2 (en) 2023-05-02

Similar Documents

Publication Publication Date Title
WO2021023154A1 (zh) 四并环类化合物及其制备方法和应用
CN104910161B (zh) 作为jak抑制剂的吡唑并嘧啶化合物和方法
CN112654619B (zh) 三环并呋喃取代哌啶二酮类化合物
WO2020048546A1 (zh) 三环取代哌啶二酮类化合物
CN111712499A (zh) 一种atr抑制剂及其应用
CN115380026A (zh) 蛋白降解调节剂与其使用方法
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN113321654B (zh) 作为激酶抑制剂的稠合吡啶酮类化合物
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
JP2022542162A (ja) ヘテロ環式アミド化合物及びその製造方法並びに使用
CN114728967A (zh) 作为jak抑制剂的三并杂环类化合物及其应用
WO2022063308A1 (zh) 一类1,7-萘啶类化合物及其应用
CN113825755A (zh) 作为irak4抑制剂的咪唑并吡啶类化合物
TW202110848A (zh) 取代的稠合雙環類衍生物、其製備方法及其在醫藥上的應用
CN113993867A (zh) 作为fgfr和vegfr双重抑制剂的并环类化合物
WO2022095909A1 (zh) 用作ntrk激酶抑制剂的化合物及其应用
CN114096245B (zh) 作为ccr2/ccr5拮抗剂的杂环烷基类化合物
CN113874379B (zh) 作为Cdc7抑制剂的四并环类化合物
CN111971285B (zh) 咪唑并吡咯酮化合物及其应用
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
WO2022222911A1 (zh) 嘧啶酮化合物及其用途
CN113166055B (zh) 雌激素受体拮抗剂
WO2021197467A1 (zh) 多靶点的抗肿瘤化合物及其制备方法和应用
CN114072396A (zh) 作为dna-pk抑制剂的喹啉和噌啉衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant